Seeking Alpha

Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders

ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics ...
Seeking Alpha

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

ENGLEWOOD CLIFFS, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics ...
Odessa American

Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial

BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trialBNC210 Phase 2b PTSD trial on target for start in mid-2021 with final ...